Globus Medical, Inc. (GMED): Price and Financial Metrics

Globus Medical, Inc. (GMED): $55.60

0.14 (+0.25%)

POWR Rating

Component Grades








Add GMED to Watchlist
Sign Up

GMED Price/Volume Stats

Current price $55.60 52-week high $80.04
Prev. close $55.46 52-week low $50.92
Day low $55.25 Volume 200,020
Day high $56.03 Avg. volume 1,405,428
50-day MA $56.50 Dividend yield N/A
200-day MA $63.15 Market Cap 5.58B

GMED Stock Price Chart Interactive Chart >


  • GMED scores best on the Quality dimension, with a Quality rank ahead of 89.06% of US stocks.
  • GMED's strongest trending metric is Value; it's been moving up over the last 179 days.
  • GMED ranks lowest in Sentiment; there it ranks in the 25th percentile.

GMED Stock Summary

  • Price to trailing twelve month operating cash flow for GMED is currently 28.63, higher than 84.89% of US stocks with positive operating cash flow.
  • For GMED, its debt to operating expenses ratio is greater than that reported by merely 0.41% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for GLOBUS MEDICAL INC; that's greater than it is for merely 10.16% of US stocks.
  • If you're looking for stocks that are quantitatively similar to GLOBUS MEDICAL INC, a group of peers worth examining would be LNN, HAE, PLPC, XGN, and KNDI.
  • GMED's SEC filings can be seen here. And to visit GLOBUS MEDICAL INC's official web site, go to

GMED Valuation Summary

  • In comparison to the median Healthcare stock, GMED's EV/EBIT ratio is 83.33% higher, now standing at 22.
  • Over the past 132 months, GMED's EV/EBIT ratio has gone up 12.2.

Below are key valuation metrics over time for GMED.

Stock Date P/S P/B P/E EV/EBIT
GMED 2023-05-23 5.1 2.9 27.3 22.0
GMED 2023-05-22 5.3 3.0 28.4 22.9
GMED 2023-05-19 5.3 2.9 28.0 22.7
GMED 2023-05-18 5.3 3.0 28.3 22.9
GMED 2023-05-17 5.3 3.0 28.3 22.9
GMED 2023-05-16 5.3 3.0 28.2 22.8

GMED Growth Metrics

    Its 2 year price growth rate is now at 28.08%.
  • The 2 year revenue growth rate now stands at 21.22%.
  • The 3 year net cashflow from operations growth rate now stands at 52.71%.
Over the past 49 months, GMED's revenue has gone up $305,301,000.

The table below shows GMED's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 998.366 190.746 155.211
2022-06-30 973.939 235.088 154.991
2022-03-31 961.307 257.394 141.946
2021-12-31 958.102 276.274 149.191
2021-09-30 941.526 280.205 187.042
2021-06-30 927.903 256.191 184.047

GMED's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GMED has a Quality Grade of B, ranking ahead of 90.91% of graded US stocks.
  • GMED's asset turnover comes in at 0.547 -- ranking 84th of 186 Medical Equipment stocks.
  • OFIX, SRTS, and ESMC are the stocks whose asset turnover ratios are most correlated with GMED.

The table below shows GMED's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.547 0.745 0.189
2021-03-31 0.514 0.729 0.131
2020-12-31 0.512 0.724 0.111
2020-09-30 0.510 0.732 0.103
2020-06-30 0.504 0.741 0.096
2020-03-31 0.542 0.764 0.165

Globus Medical, Inc. (GMED) Company Bio

Globus Medical focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company was founded in 2003 and is based in Audubon, Pennsylvania.

GMED Latest News Stream

Event/Time News Detail
Loading, please wait...

GMED Latest Social Stream

Loading social stream, please wait...

View Full GMED Social Stream

Latest GMED News From Around the Web

Below are the latest news stories about GLOBUS MEDICAL INC that investors may wish to consider to help them evaluate GMED as an investment opportunity.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.

Yahoo | May 26, 2023

Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?

Globus Medical, Inc. ( NYSE:GMED ), is not the largest company out there, but it received a lot of attention from a...

Yahoo | May 21, 2023

Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod

Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.

Yahoo | May 16, 2023

Globus Medical Announces FDA Approval for its Non-Fusion Scoliosis Correction System, the Latest Advancement for Young Patients with Idiopathic Scoliosis

REFLECT™ is approved through the FDA’s Humanitarian Device Exemption pathwayAUDUBON, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the REFLECT™ Scoliosis Correction System has been granted approval from the US Food and Drug Administration, as the company’s first humanitarian device. REFLECT™ is designed to correct progressive scoliosis in young patients while preserving motion, maintaining stability, and allo

Yahoo | May 15, 2023

Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips

The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.

Yahoo | May 5, 2023

Read More 'GMED' Stories Here

GMED Price Returns

1-mo -4.88%
3-mo -1.80%
6-mo -22.42%
1-year -10.18%
3-year -0.02%
5-year -0.32%
YTD -25.14%
2022 2.87%
2021 10.70%
2020 10.77%
2019 36.04%
2018 5.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!